Feb. 27 (EIRNS)—The U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) passed the Johnson & Johnson one-dose vaccine unanimously on Feb. 26, the company announced in a press release today. The vaccine has a 72% efficacy in the U.S. and 64% in South Africa. Against severe cases, globally, it was 85% effective. The vaccine is for those 18 years and older. It is stored at regular refrigerator temperatures.
The vaccine is the first one-dose vaccine to be approved. It can be a very important part of the fight, especially where logistics are difficult. Johnson & Johnson expects to produce and send out 20 million doses for the U.S. by March 31, and 80 million more doses by June 30. Assuming that the company gets around 25 million of the 80 million out in April, the U.S. would have vaccine doses for some 195 million Americans by the end of April—or 75% of the eligible population. Once those vaccines get into arms, the country would be in the range of herd immunity.
Dr. James Hildreth, CEO and President of Meharry Medical College, tweeted: “I am pleased to have been part of VRBPAC for review of the vaccine. We must not let a narrative take hold that this is a ‘lesser’ vaccine than the mRNA vaccines. This vaccine prevents severe disease and death and in the crisis we are in that [is] the most important thing.” For more on Dr. Hildreth’s analysis of the COVID-19 pandemic, see the Feb. 1, 2021, Schiller Institute’s Committee for the Coincidence of Opposites interview.